224,000 Shares in Haleon plc (NYSE:HLN) Purchased by Eagle Global Advisors LLC

Eagle Global Advisors LLC bought a new stake in Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 224,000 shares of the company's stock, valued at approximately $2,137,000.

Other hedge funds have also made changes to their positions in the company. Addison Advisors LLC boosted its holdings in Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after acquiring an additional 1,106 shares during the period. Haverford Trust Co grew its holdings in shares of Haleon by 5.0% in the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company's stock valued at $247,000 after purchasing an additional 1,233 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Haleon by 5.9% during the 4th quarter. Bessemer Group Inc. now owns 22,301 shares of the company's stock worth $212,000 after buying an additional 1,236 shares in the last quarter. United Capital Financial Advisors LLC grew its stake in shares of Haleon by 3.5% in the fourth quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company's stock worth $358,000 after acquiring an additional 1,266 shares in the last quarter. Finally, FIL Ltd increased its position in shares of Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after acquiring an additional 1,270 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Price Performance

Shares of HLN opened at $10.77 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1-year low of $8.12 and a 1-year high of $10.85. The stock has a market cap of $48.57 billion, a PE ratio of 31.66, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The firm has a fifty day moving average price of $10.20 and a 200 day moving average price of $9.83.

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. As a group, sell-side analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. Haleon's dividend payout ratio is 58.97%.

Analyst Ratings Changes

Several research analysts recently commented on HLN shares. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Barclays reiterated an "overweight" rating on shares of Haleon in a research note on Tuesday. HSBC reissued a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Finally, Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.